Reverse Mergers Losing Out to Lower-Cost Offerings - TheStreet
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib | Nasdaq
Puma Biotechnology shares rocket after biopharma zips past Street's 4Q estimate
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma investors look for second lightning strike | Evaluate
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology Inc. (PBYI) Stock Price, Quote & News | Stock Analysis
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology Inc. (PBYI) Stock Price, Quote & News | Stock Analysis
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Vir Biotech IPO: What You Need To Know
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Alan Auerbach: Puma Biotech's Overnight Billionaire - Forbes India
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc. IPO Investment Prospectus S-1
DFAN14A
The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo
Puma Biotechnology Inc. (NYSE: PBYI) shareholders vote against PPD founder Fred Eshelman - Triangle Business Journal
Puma Biotechnology, Inc.: Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
